PTC Therapeutics (PTCT) Posts Q4 Loss of 84c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
PTC Therapeutics (PTCT) Target Lifted to $81 at Wedbush
March 2, 2015 12:52 PM ESTWedbush analyst Heather Behanna reiterated an Outperform rating and boosted her price target on PTC Therapeutics (NASDAQ: PTCT) to $81.00 (from $68.00), noting the Translarna launch is off to a good start.
Behanna commented, "A combination of commercial launch in Germany and reimbursed expanded access... More
PTC Therapeutics (PTCT) PT Raised on BofA/Merrill Lynch on ex-US Translarna Sales
March 2, 2015 8:07 AM ESTBofA/Merrill Lynch analyst Tazeen Ahmad reiterated a Buy rating and boosted its price target on PTC Therapeutics (NASDAQ: PTCT) to $87.00 (from $60.00) following Q4 results and ex-US Translarna sales.
Ahmad notes that on the call PTC reported early ex-US launch metrics for its... More
